Clinical trials targeting FFAR4 are abundant in the treatment of diabetes-related metabolic disorders, highlighting the potential diverse utility of this receptor in the treatment of lipid- and inflammatory-related diseases [90,91]. This evidence concerns the gene FFAR4 and metabolic disease.